Clinical Trial Update: Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose intracoronary reteplase to reduce myocardial infarct size during primary PCI in acute STEMI; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St Segment Elevation Myocardial Infarction

Drugs mentioned

• Reteplase (reteplase)

Snippet

Sponsor: Ge Junbo | Conditions: Acute ST-segment Elevation Myocardial Infarction | Phase 3 | Status: TERMINATED